CHAMPIONSHIP club Nottingham Rugby has announced a sponsorship agreement with Source Bioscience, a leading international provider of integrated laboratory products and services, including COVID-19 testing.
The partnership deal – which has been agreed for the remainder of the 2021-22 season – will see Source BioScience join as one of the club’s platinum sponsors, with its logo emblazoned on the team’s playing kit. It will also feature on advertising boardings and in match-day programmes at The Bay.
Headquartered in Nottingham with facilities across Europe and the United States, Source BioScience provides bespoke services and a diverse product offering for varying precision medicine, pathology, and stability storage requirements.
Andrew Jackaman, director of Nottingham Rugby, said: “We are delighted to have Source BioScience join us as a club sponsor – an organisation that is equally proud to be based in Nottingham and thrives off talent in the city.
“Nottingham Rugby and Source BioScience have undergone recent changes to executive management and reflect similar desires to expand under a clear strategic direction, all while remaining in touch with its roots in the city. We are optimistic for the future and are thrilled to have Source BioScience join us as a club sponsor.”
Jay LeCoque, chief executive at Source BioScience, said: “It is an honour and pleasure to be supporting Nottingham Rugby. It is an ambitious club with clear intentions to improve on and off the pitch this season so we look forward to supporting the club’s hard work and efforts towards future successes.
“This sponsorship deal is a fantastic opportunity to connect with a wider audience while strengthening ties with the local community, supporting our mission to provide quality and trusted laboratory services offerings with excellent client support.”
With a focus to improve patient diagnosis, management and care, Source BioScience has recently provided COVID-19 mobile and home testing services for business and directly to the wider public.
Nick Bills, director of healthcare at Source BioScience, added: “We rapidly scaled our COVID-19 testing capabilities and are also one of the few labs in the UK who are able to quickly identify mutations. As an agile organisation, we are also primed to support NHS and private providers with tackling the backlog of elective procedures that have been delayed due to the pandemic.
“Source BioScience is at the forefront of life science innovation and we have several exciting plans in the pipeline for 2022 and beyond across our pathology, genomics, and precision medicine offerings.”